Oct 8 (Reuters) - Denmark's Zealand Pharma

said on Tuesday the U.S. Food and Drug Administration (FDA) has

issued a Complete Response Letter (CRL) relating to its drug for

preventing and treating low blood sugar in children with a

genetic disorder.

Zealand is seeking FDA approval for dasiglucagon, which it

plans to use in patients aged seven days or older with

congenital hyperinsulinism (CHI), a genetic disorder in which

the pancreas secretes too much insulin.